212 related articles for article (PubMed ID: 32183018)
1. Elevated LysoGb3 Concentration in the Neuronopathic Forms of Mucopolysaccharidoses.
Baydakova G; Ilyushkina A; Gaffke L; Pierzynowska K; Bychkov I; Ługowska A; Wegrzyn G; Tylki-Szymanska A; Zakharova E
Diagnostics (Basel); 2020 Mar; 10(3):. PubMed ID: 32183018
[TBL] [Abstract][Full Text] [Related]
2. Glycosaminoglycan levels in dried blood spots of patients with mucopolysaccharidoses and mucolipidoses.
Kubaski F; Suzuki Y; Orii K; Giugliani R; Church HJ; Mason RW; Dũng VC; Ngoc CT; Yamaguchi S; Kobayashi H; Girisha KM; Fukao T; Orii T; Tomatsu S
Mol Genet Metab; 2017 Mar; 120(3):247-254. PubMed ID: 28065440
[TBL] [Abstract][Full Text] [Related]
3. Heparan sulfate and dermatan sulfate derived disaccharides are sensitive markers for newborn screening for mucopolysaccharidoses types I, II and III.
de Ruijter J; de Ru MH; Wagemans T; Ijlst L; Lund AM; Orchard PJ; Schaefer GB; Wijburg FA; van Vlies N
Mol Genet Metab; 2012 Dec; 107(4):705-10. PubMed ID: 23084433
[TBL] [Abstract][Full Text] [Related]
4. Novel heparan sulfate assay by using automated high-throughput mass spectrometry: Application to monitoring and screening for mucopolysaccharidoses.
Shimada T; Kelly J; LaMarr WA; van Vlies N; Yasuda E; Mason RW; Mackenzie W; Kubaski F; Giugliani R; Chinen Y; Yamaguchi S; Suzuki Y; Orii KE; Fukao T; Orii T; Tomatsu S
Mol Genet Metab; 2014; 113(1-2):92-9. PubMed ID: 25092413
[TBL] [Abstract][Full Text] [Related]
5. Metabolic progression to clinical phenotype in classic Fabry disease.
Spada M; Kasper D; Pagliardini V; Biamino E; Giachero S; Porta F
Ital J Pediatr; 2017 Jan; 43(1):1. PubMed ID: 28049500
[TBL] [Abstract][Full Text] [Related]
6. Validation of disaccharide compositions derived from dermatan sulfate and heparan sulfate in mucopolysaccharidoses and mucolipidoses II and III by tandem mass spectrometry.
Tomatsu S; Montaño AM; Oguma T; Dung VC; Oikawa H; Gutiérrez ML; Yamaguchi S; Suzuki Y; Fukushi M; Barrera LA; Kida K; Kubota M; Orii T
Mol Genet Metab; 2010 Feb; 99(2):124-31. PubMed ID: 19932038
[TBL] [Abstract][Full Text] [Related]
7. Glycosaminoglycans analysis in blood and urine of patients with mucopolysaccharidosis.
Khan SA; Mason RW; Giugliani R; Orii K; Fukao T; Suzuki Y; Yamaguchi S; Kobayashi H; Orii T; Tomatsu S
Mol Genet Metab; 2018 Sep; 125(1-2):44-52. PubMed ID: 29779903
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis of Mucopolysaccharidoses and Mucolipidosis by Assaying Multiplex Enzymes and Glycosaminoglycans.
Arunkumar N; Vu DC; Khan S; Kobayashi H; Ngoc Can TB; Oguni T; Watanabe J; Tanaka M; Yamaguchi S; Taketani T; Ago Y; Ohnishi H; Saikia S; Álvarez JV; Tomatsu S
Diagnostics (Basel); 2021 Jul; 11(8):. PubMed ID: 34441282
[TBL] [Abstract][Full Text] [Related]
9. A straightforward, quantitative ultra-performance liquid chromatography-tandem mass spectrometric method for heparan sulfate, dermatan sulfate and chondroitin sulfate in urine: an improved clinical screening test for the mucopolysaccharidoses.
Zhang H; Wood T; Young SP; Millington DS
Mol Genet Metab; 2015 Feb; 114(2):123-8. PubMed ID: 25458519
[TBL] [Abstract][Full Text] [Related]
10. Heparan sulfate levels in mucopolysaccharidoses and mucolipidoses.
Tomatsu S; Gutierrez MA; Ishimaru T; Peña OM; Montaño AM; Maeda H; Velez-Castrillon S; Nishioka T; Fachel AA; Cooper A; Thornley M; Wraith E; Barrera LA; Laybauer LS; Giugliani R; Schwartz IV; Frenking GS; Beck M; Kircher SG; Paschke E; Yamaguchi S; Ullrich K; Isogai K; Suzuki Y; Orii T; Noguchi A
J Inherit Metab Dis; 2005; 28(5):743-57. PubMed ID: 16151906
[TBL] [Abstract][Full Text] [Related]
11. Pathogenic Roles of Heparan Sulfate and Its Use as a Biomarker in Mucopolysaccharidoses.
Minami K; Morimoto H; Morioka H; Imakiire A; Kinoshita M; Yamamoto R; Hirato T; Sonoda H
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233030
[TBL] [Abstract][Full Text] [Related]
12. Why are behaviors of children suffering from various neuronopathic types of mucopolysaccharidoses different?
Węgrzyn G; Jakóbkiewicz-Banecka J; Narajczyk M; Wiśniewski A; Piotrowska E; Gabig-Cimińska M; Kloska A; Słomińska-Wojewódzka M; Korzon-Burakowska A; Węgrzyn A
Med Hypotheses; 2010 Dec; 75(6):605-9. PubMed ID: 20732748
[TBL] [Abstract][Full Text] [Related]
13. Multicenter evaluation of use of dried blood spot compared to conventional plasma in measurements of globotriaosylsphingosine (LysoGb3) concentration in 104 Fabry patients.
Malvagia S; Ferri L; Della Bona M; Borsini W; Cirami CL; Dervishi E; Feriozzi S; Gasperini S; Motta S; Mignani R; Trezzi B; Pieruzzi F; Morrone A; Daniotti M; Donati MA; la Marca G
Clin Chem Lab Med; 2021 Aug; 59(9):1516-1526. PubMed ID: 33915609
[TBL] [Abstract][Full Text] [Related]
14. Validation of Liquid Chromatography-Tandem Mass Spectrometry-Based 5-Plex Assay for Mucopolysaccharidoses.
Oguni T; Tomatsu S; Tanaka M; Orii K; Fukao T; Watanabe J; Fukuda S; Notsu Y; Vu DC; Can TBN; Nagai A; Yamaguchi S; Taketani T; Gelb MH; Kobayashi H
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32188102
[TBL] [Abstract][Full Text] [Related]
15. Newborn screening for mucopolysaccharidoses: a pilot study of measurement of glycosaminoglycans by tandem mass spectrometry.
Kubaski F; Mason RW; Nakatomi A; Shintaku H; Xie L; van Vlies NN; Church H; Giugliani R; Kobayashi H; Yamaguchi S; Suzuki Y; Orii T; Fukao T; Montaño AM; Tomatsu S
J Inherit Metab Dis; 2017 Jan; 40(1):151-158. PubMed ID: 27718145
[TBL] [Abstract][Full Text] [Related]
16. Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease.
Nowak A; Mechtler TP; Hornemann T; Gawinecka J; Theswet E; Hilz MJ; Kasper DC
Mol Genet Metab; 2018 Feb; 123(2):148-153. PubMed ID: 28728877
[TBL] [Abstract][Full Text] [Related]
17. UPLC-MS/MS detection of disaccharides derived from glycosaminoglycans as biomarkers of mucopolysaccharidoses.
Auray-Blais C; Lavoie P; Tomatsu S; Valayannopoulos V; Mitchell JJ; Raiman J; Beaudoin M; Maranda B; Clarke JT
Anal Chim Acta; 2016 Sep; 936():139-48. PubMed ID: 27566349
[TBL] [Abstract][Full Text] [Related]
18. A Multiplex Assay for the Diagnosis of Mucopolysaccharidoses and Mucolipidoses.
Langereis EJ; Wagemans T; Kulik W; Lefeber DJ; van Lenthe H; Oussoren E; van der Ploeg AT; Ruijter GJ; Wevers RA; Wijburg FA; van Vlies N
PLoS One; 2015; 10(9):e0138622. PubMed ID: 26406883
[TBL] [Abstract][Full Text] [Related]
19. α-Galactosidase A/lysoGb3 ratio as a potential marker for Fabry disease in females.
Baydakova GV; Ilyushkina AA; Moiseev S; Bychkov IO; Nikitina NV; Buruleva ТА; Zakharova EY
Clin Chim Acta; 2020 Feb; 501():27-32. PubMed ID: 31770509
[TBL] [Abstract][Full Text] [Related]
20. Plasma globotriaosylsphingosine (lysoGb3) could be a biomarker for Fabry disease with a Chinese hotspot late-onset mutation (IVS4+919G>A).
Liao HC; Huang YH; Chen YJ; Kao SM; Lin HY; Huang CK; Liu HC; Hsu TR; Lin SP; Yang CF; Fann CS; Chiu PC; Hsieh KS; Fu YC; Ke YY; Lin CY; Tsai FJ; Wang CH; Chao MC; Yu WC; Chiang CC; Niu DM
Clin Chim Acta; 2013 Nov; 426():114-20. PubMed ID: 24055776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
